Arnab Chakravarti

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. doi request reprint RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients
    Arnab Chakravarti
    Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L Solove Research Institute, The Ohio State University, Columbus, Ohio, USA
    Int J Radiat Oncol Biol Phys 85:1206-11. 2013
  2. ncbi request reprint Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway
    Gary G Zhai
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA, 02114, USA
    J Neurooncol 76:227-37. 2006
  3. pmc The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group
    Prakash Chinnaiyan
    Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, USA
    Radiat Oncol 3:32. 2008
  4. doi request reprint Survivin is a potential mediator of prostate cancer metastasis
    Min Zhang
    Arthur G James Comprehensive Cancer Center, The Ohio State University Medical School, Columbus, OH 43210, USA
    Int J Radiat Oncol Biol Phys 78:1095-103. 2010
  5. ncbi request reprint Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo
    Min Zhang
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School Boston, Massachusetts 02114, USA
    Prostate 64:293-302. 2005
  6. ncbi request reprint The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, 02114, USA
    J Clin Oncol 22:1926-33. 2004
  7. ncbi request reprint Current therapeutic paradigms in glioblastoma
    Allison Quick
    Department of Radiation Oncology, Ohio State University, Madison, WI, 53792, USA
    Rev Recent Clin Trials 5:14-27. 2010
  8. pmc Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma
    E Antonio Chiocca
    James Cancer Hospital Ohio State University Medical Center, N 1017 Doan Hall, 410 W 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:3611-9. 2011
  9. ncbi request reprint Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston 02114, USA
    Oncogene 23:7494-506. 2004
  10. ncbi request reprint Overcoming therapeutic resistance in malignant gliomas: current practices and future directions
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, USA
    Cancer Treat Res 139:173-89. 2008

Research Grants

  1. Signal Transduction Pathways in Glioblastoma
    Arnab Chakravarti; Fiscal Year: 2007
  2. Signal Transduction Pathways in Glioblastoma
    Arnab Chakravarti; Fiscal Year: 2009

Collaborators

Detail Information

Publications46

  1. doi request reprint RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients
    Arnab Chakravarti
    Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L Solove Research Institute, The Ohio State University, Columbus, Ohio, USA
    Int J Radiat Oncol Biol Phys 85:1206-11. 2013
    ..To determine the safety and efficacy of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed glioblastoma (GBM) patients...
  2. ncbi request reprint Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway
    Gary G Zhai
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA, 02114, USA
    J Neurooncol 76:227-37. 2006
    ..This report clearly demonstrates that radiation-mediated invasion is fundamentally distinct from invasion under normal cellular physiology and identifies potential therapeutic targets to overcome this phenomenon...
  3. pmc The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group
    Prakash Chinnaiyan
    Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, USA
    Radiat Oncol 3:32. 2008
    ....
  4. doi request reprint Survivin is a potential mediator of prostate cancer metastasis
    Min Zhang
    Arthur G James Comprehensive Cancer Center, The Ohio State University Medical School, Columbus, OH 43210, USA
    Int J Radiat Oncol Biol Phys 78:1095-103. 2010
    ..We examined whether Survivin expression is associated with an increased risk of metastasis in prostate cancer...
  5. ncbi request reprint Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo
    Min Zhang
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School Boston, Massachusetts 02114, USA
    Prostate 64:293-302. 2005
    ..The purpose of this study is to investigate the role of Survivin in paclitaxel-resistance and whether the targeting of Survivin sensitizes prostate cancer cells to paclitaxel...
  6. ncbi request reprint The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, 02114, USA
    J Clin Oncol 22:1926-33. 2004
    ..The objectives of this study were to examine activation patterns of the phosphatidylinositol 3-kinase (PI3K) pathway in gliomas and to examine the prognostic significance of PI3K pathway activation using snap-frozen clinical specimens...
  7. ncbi request reprint Current therapeutic paradigms in glioblastoma
    Allison Quick
    Department of Radiation Oncology, Ohio State University, Madison, WI, 53792, USA
    Rev Recent Clin Trials 5:14-27. 2010
    ..This article will review the current therapies for GBM and the investigation of new molecular and targeted therapies, such as EGFR inhibitors, mTOR/PI3Kinase inhibitors, and anti-angiogenesis agents...
  8. pmc Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma
    E Antonio Chiocca
    James Cancer Hospital Ohio State University Medical Center, N 1017 Doan Hall, 410 W 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:3611-9. 2011
    ....
  9. ncbi request reprint Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston 02114, USA
    Oncogene 23:7494-506. 2004
    ....
  10. ncbi request reprint Overcoming therapeutic resistance in malignant gliomas: current practices and future directions
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, USA
    Cancer Treat Res 139:173-89. 2008
    ..Emerging data from clinical studies on "first generation" targeted therapies appear to demonstrate benefit for select patients. Further molecular/genetic profiling must be undertaken to identify exactly which patients benefit...
  11. pmc Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202
    Arnab Chakravarti
    Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
    J Clin Oncol 25:3082-9. 2007
    ..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
  12. ncbi request reprint Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, 02114, USA
    Clin Cancer Res 12:4738-46. 2006
    ..In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells...
  13. ncbi request reprint Survivin mediates resistance to antiandrogen therapy in prostate cancer
    Min Zhang
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Oncogene 24:2474-82. 2005
    ..Targeted inhibition of Survivin appears to enhance the therapeutic effects of Flutamide in vitro and in vivo, revealing a novel strategy to enhance sensitivity to androgen ablation therapy...
  14. pmc Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells
    Min Zhang
    Department of Radiation Oncology, The Ohio State University Medical School, Columbus, Ohio, USA
    Prostate 70:807-16. 2010
    ..p21-activated kinase 6 (PAK6) is a serine/threonine kinase belonging to the p21-activated kinase (PAK) family. We investigated the role of PAK6 in radiation-induced cell death in human prostate cancer cells...
  15. ncbi request reprint The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Cancer Res 62:4307-15. 2002
    ..Therefore, these findings suggest that strategies to inactivate EGFR or RAS signaling may be critical to improving not only the efficacy of single-agent therapy but also of combined modality therapy in gliomas...
  16. doi request reprint Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival
    Tim Lautenschlaeger
    Department of Radiation Oncology, Wexner Medical Center, Ohio State University, Columbus, Ohio 43210, USA
    Oncologist 18:685-6. 2013
    ..We investigated vascular endothelial growth factor (VEGF) pathway biomarkers in this unique clinical dataset (median follow-up of 3.1 years)...
  17. ncbi request reprint Impact of molecular profiling on clinical trial design for glioblastoma
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    Curr Oncol Rep 9:71-9. 2007
    ..The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy...
  18. ncbi request reprint Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 62:318-27. 2005
    ....
  19. doi request reprint Technological advances in radiation oncology for central nervous system tumors
    Shin Ei Noda
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Semin Radiat Oncol 19:179-86. 2009
    ..This review article discusses how these advances have changed the way in which many common neoplasms of the central nervous system are being treated at present...
  20. ncbi request reprint Molecular profiling in glioblastoma: prelude to personalized treatment
    Nikol Mladkova
    Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Curr Oncol Rep 11:53-61. 2009
    ....
  21. ncbi request reprint The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 58:927-31. 2004
    ..The epidermal growth factor receptor (EGFR) pathway is frequently upregulated in high-grade gliomas via gene amplification and by specific mutations that render EGFR constitutively active (EGFRvIII)...
  22. doi request reprint Recent advancements in multimodality treatment of gliomas
    Mersiha Hadziahmetovic
    Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L Solove Research Institute, The Ohio State University Medical Center, Columbus, 43210, USA
    Future Oncol 7:1169-83. 2011
    ..Moreover, the external beam radiotherapy options, including intensity modulated radiotherapy and particle (proton and carbon ion) radiotherapy are reviewed...
  23. doi request reprint Molecular advances of brain tumors in radiation oncology
    Shin Ei Noda
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Semin Radiat Oncol 19:171-8. 2009
    ..It is hoped that this combined approach will overcome the current limitations in the treatment of patients with glioblastoma and result in a better prognosis for these patients...
  24. pmc Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues
    Wei Meng
    Department of Radiation Oncology, Wexner Medical Center, and Richard L Solove Research Institute, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e64393. 2013
    ..Ligation-based microRNA deep sequencing on FFPE cancer tissues is feasible and RNA degradation to the degree observed in our study appears to not affect the number of microRNAs that can be quantified...
  25. pmc In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines
    Tim Lautenschlaeger
    Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA
    Radiat Oncol 8:246. 2013
    ..The ability of cilengitide to enhance the effects of radiation was examined preclinically in the setting of breast cancer to assess its possible efficacy in the setting of brain metastasis from breast cancer...
  26. ncbi request reprint Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma
    Paul L Nguyen
    Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:1507-13. 2005
    ..This study evaluates the efficacy and toxicity of whole-brain radiation therapy (WBRT) as salvage therapy for immunocompetent patients who failed initial high-dose methotrexate for primary CNS lymphoma (PCNSL)...
  27. doi request reprint Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison
    Malika L Siker
    Department of Radiation Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    J Neurooncol 104:351-6. 2011
    ..1-3.6% of our patients. They have superior survival, even when adjusted for RPA class. More investigations on the unique biologic and clinical characteristics of tumors in this population are needed...
  28. ncbi request reprint Novel radiation-enhancing agents in malignant gliomas
    Min Zhang
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Semin Radiat Oncol 16:29-37. 2006
    ..This article will review the role of both traditional nitrosurea-based and newer-generation chemotherapeutic and biotherapeutic agents when combined with radiation therapy for the treatment of malignant glioma patients...
  29. ncbi request reprint Molecular and genetic profiling in human gliomas
    Kamalakannan Palanichamy
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    Discov Med 7:75-81. 2007
    ..Through molecular and genetic profiling, it has been possible to both identify mechanisms of disease progression and its therapeutic resistance. This paper highlights the significance of these advances...
  30. ncbi request reprint Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemot
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 62:309-17. 2005
    ....
  31. ncbi request reprint Biomarkers of clinical responsiveness in brain tumor patients : progress and potential
    Areej El-Jawahri
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
    Mol Diagn Ther 12:199-208. 2008
    ..Research into the clinical relevance and applicability of such biomarkers has the potential to revolutionize our approach to the diagnosis and treatment of patients with malignant gliomas...
  32. pmc MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma
    Wei Meng
    Authors Affiliations Department of Molecular Medicine, The University of Texas Health Science Center, San Antonio, Texas Department of Radiation Oncology, Department of Molecular Virology, Immunology and Medical Genetics Comprehensive Cancer Center Department of Pathology, College of Medicine Department of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, Ohio and Yanbian University College of Medicine, Ji Lin, China
    Clin Cancer Res 19:5423-33. 2013
    ..We conducted genome-wide miRNA-sequencing (miRNA-seq) in primary cancer tissue from patients of lung adenocarcinoma to identify markers for the presence of lymph node metastasis...
  33. doi request reprint Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques
    Jenna Kahn
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 81:232-8. 2011
    ....
  34. ncbi request reprint Quantitatively determined survivin expression levels are of prognostic value in human gliomas
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    J Clin Oncol 20:1063-8. 2002
    ..Its expression has been found to be of prognostic significance in several tumor types. This is the first study on the prognostic significance of survivin expression in human gliomas...
  35. ncbi request reprint Predictive and prognostic markers in human glioblastomas
    Kamalakannan Palanichamy
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    Curr Treat Options Oncol 7:490-504. 2006
    ..As more effective "smart drugs" are developed, molecular and genetic profiling will assume even greater importance in this regard...
  36. pmc Combining drugs and radiotherapy: from the bench to the bedside
    Kamalakannan Palanichamy
    Department of Radiation Oncology, The Ohio State University Medical School, Columbus, Ohio 43210, USA
    Curr Opin Neurol 22:625-32. 2009
    ..This review addresses some of the relevant issues...
  37. doi request reprint Towards personalized therapy for patients with glioblastoma
    Katsuyuki Shirai
    Department of Radiation Oncology, The Ohio State University Medical School, 300 W 10th Avenue, Columbus, OH 43210, USA
    Expert Rev Anticancer Ther 11:1935-44. 2011
    ..In this article, we review the recent studies that can provide personalized therapy for glioblastoma, based on molecular tumor profiling or patients' physical status...
  38. doi request reprint Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle
    Somsundaram N Chettiar
    Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210 1291, United States
    Bioorg Med Chem Lett 23:5429-33. 2013
    ....
  39. pmc An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway
    Deliang Guo
    Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University Medical School, Columbus, OH, USA
    Cancer Discov 1:442-56. 2011
    ..These results show that EGFRvIII can promote tumor survival through PI3K/SREBP-1-dependent upregulation of LDLR and suggest a role for LXR agonists in the treatment of GBM patients...
  40. ncbi request reprint The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects
    Ulf Nestler
    Molecular Neuro oncology Laboratory, Department of Radiation Oncology, Massachusetts General Hospital East, Charlestown, MA, USA
    J Neurooncol 67:177-88. 2004
    ..In the present study, we adopted this approach for the treatment of human glioblastoma xenografts in an athymic mouse model and assessed treatment results as well as toxic side effects...
  41. pmc Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas
    Katsuyuki Shirai
    Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Oncol 2012:193436. 2012
    ..Specific severe side effects, difficult assessment of response, and lack of rational predictive markers are challenging problems. Further studies are warranted to establish the optimized antiangiogenesis therapy for malignant gliomas...
  42. ncbi request reprint Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Cancer Res 62:200-7. 2002
    ..These findings suggest that IGFR-I signaling through phosphoinositide 3-kinase may represent a novel and potentially important mechanism of resistance to anti-EGFR therapy...
  43. pmc Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer
    Wei Meng
    Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA
    Mol Biol Int 2012:701814. 2012
    ..854, suggesting that promoter methylation analysis of RASSF1A and RASSF2A genes has potential for use as a recurrence biomarker for bladder cancer patients...
  44. pmc Novel therapies in glioblastoma
    James Perry
    Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA
    Neurol Res Int 2012:428565. 2012
    ..A better understanding of underlying tumor biology may yield insights into optimal targeting strategies which could improve the overall therapeutic ratio of conventional treatments...
  45. pmc Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation
    Naduparambil K Jacob
    Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, 410 W 12th Ave, Columbus, OH 43210, USA
    Onco Targets Ther 5:7-20. 2012
    ..Thus, our study establishes survivin as a marker of proliferation, rather than a cancer specific marker. Therefore, systemic therapeutic interventions targeting survivin will affect cancer as well as normal proliferating cells...
  46. pmc Identification of sensitive serum microRNA biomarkers for radiation biodosimetry
    Naduparambil Korah Jacob
    Department of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e57603. 2013
    ....

Research Grants5

  1. Signal Transduction Pathways in Glioblastoma
    Arnab Chakravarti; Fiscal Year: 2007
    ....
  2. Signal Transduction Pathways in Glioblastoma
    Arnab Chakravarti; Fiscal Year: 2009
    ....